Novavax and Moderna shares have started to fall. The reasons are as follows: Novavax has postponed its application to the FDA, and its quarterly report is weak, while Moderna shares are naturally correcting. Tech analysis of Novavax and Moderna shares.
All posts
3 min
The US FDA approved a drug by Biogen called Aduhelm (aducanumab) for curing Alzheimer’s. Biogen shares grew by 38.34%.
9 min
COVID-19. Unofficially, we have a vaccine. Officially, we might have it in May.
11 min
The FDA plays an integral part in analyzing companies and determining their potential. At the stage of approbation, 95% of companies work at a loss, that is why the financial analysis will show nothing.